Form 4: 4D Molecular Therapeutics: Insider Stock Transactions

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports transactions involving the purchase and sale of company stock.

Summary

• Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, Inc. (FDMT), engaged in stock transactions on June 23, 2026.
• He acquired 9,810 shares of common stock at a price of $4.14 per share.
• Concurrently, he disposed of 9,810 shares of common stock at a price of $12 per share.
• Following these transactions, Bizily beneficially owns 8,617 shares of common stock directly.
• An additional 63,785 shares are held indirectly through a stock option.
• The acquisition of 5,023 shares was made under the company's Employee Stock Purchase Plan, exempt under Rule 16b-3.
• The stock option, with an exercise price of $4.14, has a vesting commencement date of March 6, 2025, with full vesting occurring on the fourth anniversary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider transactions including participation in employee plans and profit-taking, without strong indicators of significant positive or negative sentiment towards the company's future.

Positives

• Acquisition of shares at a lower price ($4.14) suggests a belief in future stock appreciation.
• Participation in the Employee Stock Purchase Plan indicates employee engagement and potential long-term commitment.
• The stock option award, while not immediately exercised, represents potential future equity value for management.

Negatives

• Sale of shares at a higher price ($12) could indicate profit-taking by management.
• The net effect of the transactions is a reduction in directly held common stock.

Risks

• The filing does not explicitly mention any risks.
• Potential for future insider selling could put downward pressure on the stock price.

Future Outlook

The stock option award indicates a future potential increase in equity for the reporting person, contingent on continued service and vesting schedules.

Management Comments

• The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, providing transparency into insider stock transactions. These filings are closely watched by investors to gauge management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: Increased transparency into insider activity, potentially influencing investment decisions.
• Employees: The Employee Stock Purchase Plan participation highlights a benefit available to employees, fostering engagement.
• Management: The transactions reflect personal financial decisions of a key executive.

Next Steps

• Continued vesting of stock options according to the outlined schedule.
• Potential future transactions by Scott Bizily, which will be disclosed via subsequent Form 4 filings.

Key Dates

Keywords

Form 4, Insider Trading, Stock Transaction, 4D Molecular Therapeutics, FDMT, Scott Bizily, Chief Legal Officer, Common Stock, Stock Option, Employee Stock Purchase Plan, Beneficial Ownership